Abbott Laboratories (ABT.N)
59.19USD
9:01pm BST
$-0.69 (-1.15%)
$59.88
$59.95
$59.95
$58.82
1,995,088
1,914,484
$64.60
$42.88
About
Overall
| Beta: | 1.57 |
| Market Cap(Mil.): | $95,559.38 |
| Shares Outstanding(Mil.): | 1,737.44 |
| Dividend: | 0.26 |
| Yield (%): | 1.93 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 84.45 | 30.95 | 32.74 |
| EPS (TTM): | 0.65 | -- | -- |
| ROI: | 2.24 | 14.84 | 14.38 |
| ROE: | 4.07 | 16.34 | 16.07 |
Abbott sticks to earlier forecasts, disappoints investors
Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.
UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors
* Analysts cite disappointment on whisper numbers among investors
BRIEF-Abbott Q1 GAAP Earnings Per Share $0.23 From Continuing Operations
* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS
Abbott Labs' quarterly revenue rises 16.7 percent
April 18 Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.
BRIEF-Abbott Initiates Groundbreaking Study To Assess Superiority Of High-Resolution Imaging Versus Standard-Of Care Angiography In Treating Coronary Artery Disease
* RESOLUTION IMAGING RESULT IN LARGER VESSEL DIAMETERS Source text for Eikon: Further company coverage:
RPT-UPDATE 1-Smith & Nephew picks new CEO who sold his last company
LONDON, April 4 Artificial hip and knee maker Smith & Nephew, a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making.
BRIEF-Abbott Initiates Trial To Evaluate Improved Survival And Outcomes With The Cardiomems Monitor
* ABBOTT INITIATES TRIAL TO EVALUATE IMPROVED SURVIVAL AND OUTCOMES WITH THE CARDIOMEMS MONITOR
Abbott's Alere resolves U.S. diagnostic device probe for $33.2 mln
BOSTON, March 23 Alere Inc has agreed to pay $33.2 million to resolve claims it knowingly sold unreliable diagnostic testing devices to hospitals prior to its acquisition by Abbott Laboratories last year, the U.S. Justice Department said on Friday.
BRIEF-Abbott's MitraClip Therapy Receives National Reimbursement In Japan To Treat Patients With Mitral Regurgitation
* ABBOTT'S MITRACLIP THERAPY RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PATIENTS WITH MITRAL REGURGITATION
BRIEF-Abbott Laboratories CEO Miles White's Total Compensation,Without Change In Pension Value Was $16.8 Mln V/s $17.4 Million In 2016
* ABBOTT LABORATORIES CEO MILES D. WHITE'S 2017 TOTAL COMPENSATION(TOTAL WITHOUT CHANGE IN PENSION VALUE) WAS $16.8 MILLION VERSUS $17.4 MILLION IN 2016 – SEC FILING Source text (http://bit.ly/2IwpJvl) Further company coverage: (Reuters.Brief@thomsonreuters.com)
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $126.66 | -0.89 |
| Pfizer Inc. (PFE.N) | $36.63 | +0.10 |
| Novartis AG (NOVN.S) | CHF76.08 | -1.20 |
| Merck & Co., Inc. (MRK.N) | $58.83 | +0.19 |
| Sanofi SA (SASY.PA) | €65.28 | -0.32 |
| AstraZeneca plc (AZN.L) | 4,976.00 | +20.50 |
| GlaxoSmithKline plc (GSK.L) | 1,430.00 | +22.60 |
| Eli Lilly And Co (LLY.N) | $79.06 | -0.69 |
| Amgen, Inc. (AMGN.OQ) | $171.56 | -1.37 |
| Boston Scientific Corporation (BSX.N) | $28.84 | -0.05 |
Estimates